Compare Repligen Corporation Common Stock (RGEN) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs SpaceX — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while SpaceX trades at $148.7 (market cap $2.12T). The key difference: SpaceX is far larger — about 190.3× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, SpaceX nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and SpaceX for 42 Days on average.
| RGEN | SPCX | |
|---|---|---|
Market Cap | $11.14B | $2.12T |
Volume | 1,259,263 | 68,438,228 |
Sector | Health | Industrials |
52-Week High | $194.57 | $202.09 |
52-Week Low | $102.87 | $108.27 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $11.02B | $2.06T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SpaceX (SPCX) trades at $156.54, down 4.21% amid broader market weakness despite recent operational successes. Technical indicators show a bullish trend with strong institutional buying support. The company maintains robust revenue growth projections ($23B for 2026) but faces profitability challenges with negative net margins (-35.66%) and elevated valuations (P/S 72.26). Recent news highlights Starlink's expansion into wireless markets while geopolitical tensions create operational complexities.
Long-term growth prospects remain compelling given SpaceX's dominant market position and Starlink expansion, though current valuations require substantial future execution. Key risks include execution on massive capital expenditures, competitive pressures in satellite communications, and geopolitical sensitivities. Analyst consensus remains strongly bullish with a $211.43 price target representing 35% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
